Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2004 Mar;80(941):155–164. doi: 10.1136/pgmj.2003.007062

Antiplatelet therapy in cardiovascular disease

M Behan 1, R Storey 1
PMCID: PMC1742947  PMID: 15016937

Full Text

The Full Text of this article is available as a PDF (446.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman E. M., Giugliano R. P., Gibson C. M., McCabe C. H., Coussement P., Kleiman N. S., Vahanian A., Adgey A. A., Menown I., Rupprecht H. J. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999 Jun 1;99(21):2720–2732. doi: 10.1161/01.cir.99.21.2720. [DOI] [PubMed] [Google Scholar]
  2. Bertrand M. E., Rupprecht H. J., Urban P., Gershlick A. H., CLASSICS Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000 Aug 8;102(6):624–629. doi: 10.1161/01.cir.102.6.624. [DOI] [PubMed] [Google Scholar]
  3. Brener S. J., Barr L. A., Burchenal J. E., Katz S., George B. S., Jones A. A., Cohen E. D., Gainey P. C., White H. J., Cheek H. B. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998 Aug 25;98(8):734–741. doi: 10.1161/01.cir.98.8.734. [DOI] [PubMed] [Google Scholar]
  4. Buerke M., Pittroff W., Meyer J., Darius H. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J. 1995 Sep;130(3 Pt 1):465–472. doi: 10.1016/0002-8703(95)90353-4. [DOI] [PubMed] [Google Scholar]
  5. Cairns J. A., Gent M., Singer J., Finnie K. J., Froggatt G. M., Holder D. A., Jablonsky G., Kostuk W. J., Melendez L. J., Myers M. G. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313(22):1369–1375. doi: 10.1056/NEJM198511283132201. [DOI] [PubMed] [Google Scholar]
  6. Cannon C. P., McCabe C. H., Wilcox R. G., Langer A., Caspi A., Berink P., Lopez-Sendon J., Toman J., Charlesworth A., Anders R. J. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000 Jul 11;102(2):149–156. doi: 10.1161/01.cir.102.2.149. [DOI] [PubMed] [Google Scholar]
  7. Cannon C. P., Weintraub W. S., Demopoulos L. A., Vicari R., Frey M. J., Lakkis N., Neumann F. J., Robertson D. H., DeLucca P. T., DiBattiste P. M. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001 Jun 21;344(25):1879–1887. doi: 10.1056/NEJM200106213442501. [DOI] [PubMed] [Google Scholar]
  8. Chew D. P., Moliterno D. J. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol. 2000 Dec;36(7):2028–2035. doi: 10.1016/s0735-1097(00)00979-7. [DOI] [PubMed] [Google Scholar]
  9. Clemetson K. J. Platelet activation: signal transduction via membrane receptors. Thromb Haemost. 1995 Jul;74(1):111–116. [PubMed] [Google Scholar]
  10. Coller B. S. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost. 2001 Jul;86(1):427–443. [PubMed] [Google Scholar]
  11. Coller B. S. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost. 2001 Jul;86(1):427–443. [PubMed] [Google Scholar]
  12. Davies M. J. The pathophysiology of acute coronary syndromes. Heart. 2000 Mar;83(3):361–366. doi: 10.1136/heart.83.3.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Davies M. J. The pathophysiology of acute coronary syndromes. Heart. 2000 Mar;83(3):361–366. doi: 10.1136/heart.83.3.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Derry S., Loke Y. K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 Nov 11;321(7270):1183–1187. doi: 10.1136/bmj.321.7270.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Diener H. C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1–13. doi: 10.1016/s0022-510x(96)00308-5. [DOI] [PubMed] [Google Scholar]
  16. Diener H. C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1–13. doi: 10.1016/s0022-510x(96)00308-5. [DOI] [PubMed] [Google Scholar]
  17. Eisert W. G. How to get from antiplatelet to antithrombotic treatment. Am J Ther. 2001 Nov-Dec;8(6):443–449. doi: 10.1097/00045391-200111000-00009. [DOI] [PubMed] [Google Scholar]
  18. Falk E., Shah P. K., Fuster V. Coronary plaque disruption. Circulation. 1995 Aug 1;92(3):657–671. doi: 10.1161/01.cir.92.3.657. [DOI] [PubMed] [Google Scholar]
  19. Fernández-Ortiz A., Badimon J. J., Falk E., Fuster V., Meyer B., Mailhac A., Weng D., Shah P. K., Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994 Jun;23(7):1562–1569. doi: 10.1016/0735-1097(94)90657-2. [DOI] [PubMed] [Google Scholar]
  20. Fitzgerald D. J., Catella F., Roy L., FitzGerald G. A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1988 Jan;77(1):142–150. doi: 10.1161/01.cir.77.1.142. [DOI] [PubMed] [Google Scholar]
  21. Fuster V., Badimon L., Badimon J. J., Chesebro J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992 Jan 23;326(4):242–250. doi: 10.1056/NEJM199201233260406. [DOI] [PubMed] [Google Scholar]
  22. Hobbach H-P, Schuster P. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Z Kardiol. 2003 Mar;92(3):213–218. doi: 10.1007/s00392-003-0895-6. [DOI] [PubMed] [Google Scholar]
  23. Juul-Möller S., Edvardsson N., Jahnmatz B., Rosén A., Sørensen S., Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992 Dec 12;340(8833):1421–1425. doi: 10.1016/0140-6736(92)92619-q. [DOI] [PubMed] [Google Scholar]
  24. Lewis H. D., Jr, Davis J. W., Archibald D. G., Steinke W. E., Smitherman T. C., Doherty J. E., 3rd, Schnaper H. W., LeWinter M. M., Linares E., Pouget J. M. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. doi: 10.1056/NEJM198308183090703. [DOI] [PubMed] [Google Scholar]
  25. Manson J. E., Grobbee D. E., Stampfer M. J., Taylor J. O., Goldhaber S. Z., Gaziano J. M., Ridker P. M., Buring J. E., Hennekens C. H. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med. 1990 Dec;89(6):772–776. doi: 10.1016/0002-9343(90)90220-8. [DOI] [PubMed] [Google Scholar]
  26. Mehta S. R., Yusuf S., Peters R. J., Bertrand M. E., Lewis B. S., Natarajan M. K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 Aug 18;358(9281):527–533. doi: 10.1016/s0140-6736(01)05701-4. [DOI] [PubMed] [Google Scholar]
  27. Monroe Dougald M., Hoffman Maureane, Roberts Harold R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1381–1389. doi: 10.1161/01.atv.0000031340.68494.34. [DOI] [PubMed] [Google Scholar]
  28. Montalescot G., Barragan P., Wittenberg O., Ecollan P., Elhadad S., Villain P., Boulenc J. M., Morice M. C., Maillard L., Pansiéri M. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001 Jun 21;344(25):1895–1903. doi: 10.1056/NEJM200106213442503. [DOI] [PubMed] [Google Scholar]
  29. Noble S., Goa K. L. Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging. 1996 Mar;8(3):214–232. doi: 10.2165/00002512-199608030-00006. [DOI] [PubMed] [Google Scholar]
  30. O'Shea J. Conor, Buller Christopher E., Cantor Warren J., Chandler A. Bleakley, Cohen Eric A., Cohen David J., Gilchrist Ian C., Kleiman Neal S., Labinaz Marino, Madan Mina. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2002 Feb 6;287(5):618–621. doi: 10.1001/jama.287.5.618. [DOI] [PubMed] [Google Scholar]
  31. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994 May 5;330(18):1287–1294. doi: 10.1056/NEJM199405053301808. [DOI] [PubMed] [Google Scholar]
  32. Pawar D., Shahani S., Maroli S. Aspirin---the novel antiplatelet drug. Hong Kong Med J. 1998 Dec;4(4):415–418. [PubMed] [Google Scholar]
  33. Ridker P. M., Manson J. E., Gaziano J. M., Buring J. E., Hennekens C. H. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1991 May 15;114(10):835–839. doi: 10.7326/0003-4819-114-10-835. [DOI] [PubMed] [Google Scholar]
  34. Robbie L. A., Booth N. A., Croll A. M., Bennett B. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost. 1993 Aug 2;70(2):301–306. [PubMed] [Google Scholar]
  35. Roderick P. J., Wilkes H. C., Meade T. W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol. 1993 Mar;35(3):219–226. doi: 10.1111/j.1365-2125.1993.tb05689.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115–126. doi: 10.1056/NEJM199901143400207. [DOI] [PubMed] [Google Scholar]
  37. Sans S., Kesteloot H., Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997 Dec;18(12):1231–1248. [PubMed] [Google Scholar]
  38. Savi P., Nurden P., Nurden A. T., Levy-Toledano S., Herbert J. M. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9(3-4):251–255. doi: 10.1080/09537109876799. [DOI] [PubMed] [Google Scholar]
  39. Scarborough R. M. Development of eptifibatide. Am Heart J. 1999 Dec;138(6 Pt 1):1093–1104. doi: 10.1016/s0002-8703(99)70075-x. [DOI] [PubMed] [Google Scholar]
  40. Schömig A., Neumann F. J., Kastrati A., Schühlen H., Blasini R., Hadamitzky M., Walter H., Zitzmann-Roth E. M., Richardt G., Alt E. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996 Apr 25;334(17):1084–1089. doi: 10.1056/NEJM199604253341702. [DOI] [PubMed] [Google Scholar]
  41. Shattil S. J. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost. 1995 Jul;74(1):149–155. [PubMed] [Google Scholar]
  42. Shattil S. J. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost. 1995 Jul;74(1):149–155. [PubMed] [Google Scholar]
  43. Simoons M. L., GUSTO IV-ACS Investigators Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001 Jun 16;357(9272):1915–1924. doi: 10.1016/s0140-6736(00)05060-1. [DOI] [PubMed] [Google Scholar]
  44. Steinhubl Steven R., Berger Peter B., Mann J. Tift, 3rd, Fry Edward T. A., DeLago Augustin, Wilmer Charles, Topol Eric J., CREDO Investigators. Clopidogrel for the Reduction of Events During Observation Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411–2420. doi: 10.1001/jama.288.19.2411. [DOI] [PubMed] [Google Scholar]
  45. Stone Gregg W., Grines Cindy L., Cox David A., Garcia Eulogio, Tcheng James E., Griffin John J., Guagliumi Giulio, Stuckey Thomas, Turco Mark, Carroll John D. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002 Mar 28;346(13):957–966. doi: 10.1056/NEJMoa013404. [DOI] [PubMed] [Google Scholar]
  46. Storey Robert F., Judge Heather M., Wilcox Robert G., Heptinstall Stan. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002 Sep;88(3):488–494. [PubMed] [Google Scholar]
  47. Storey Robert F., Wilcox Robert G., Heptinstall Stan. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002 Nov;13(7):407–413. doi: 10.1080/0953710021000024402. [DOI] [PubMed] [Google Scholar]
  48. Théroux P., Ouimet H., McCans J., Latour J. G., Joly P., Lévy G., Pelletier E., Juneau M., Stasiak J., deGuise P. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988 Oct 27;319(17):1105–1111. doi: 10.1056/NEJM198810273191701. [DOI] [PubMed] [Google Scholar]
  49. Topol E. J., GUSTO V Investigators Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001 Jun 16;357(9272):1905–1914. doi: 10.1016/s0140-6736(00)05059-5. [DOI] [PubMed] [Google Scholar]
  50. Topol E. J., Mark D. B., Lincoff A. M., Cohen E., Burton J., Kleiman N., Talley D., Sapp S., Booth J., Cabot C. F. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999 Dec 11;354(9195):2019–2024. doi: 10.1016/s0140-6736(99)10018-7. [DOI] [PubMed] [Google Scholar]
  51. Topol E. J., Moliterno D. J., Herrmann H. C., Powers E. R., Grines C. L., Cohen D. J., Cohen E. A., Bertrand M., Neumann F. J., Stone G. W. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001 Jun 21;344(25):1888–1894. doi: 10.1056/NEJM200106213442502. [DOI] [PubMed] [Google Scholar]
  52. Torr-Brown S. R., Sobel B. E. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res. 1993 Dec 1;72(5):413–421. doi: 10.1016/0049-3848(93)90241-f. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES